Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy
Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy
复制标题
DOI：
10.1016/s1590-8658(03)00432-8
复制
发表时间：
2003-10-01
影响因子：
4.5
通讯作者：
Kasuga, M
中科院分区：
文献类型：
--
作者：
Watanabe, Y;Aoyama, N;Kasuga, M
背景标准三联疗法失败后，成功根除幽门螺杆菌感染是困难的。目的：评价以左氧氟沙星为基础的三联疗法作为一线治疗的有效性和安全性。目的是评估标准三联疗法失败后左氧氟沙星治疗的疗效和耐受性。我们进行了一项前瞻性、非对照研究，连续纳入33例兰索拉唑-阿莫西林-克拉霉素三联治疗1周失败的患者。受试者接受为期1周的LA-LVFX三联疗法（兰索拉唑，30 mg，每日2次;阿莫西林，1000 mg，每日2次;左氧氟沙星，200 mg，每日2次）重新治疗。二线治疗后4 ~ 8周，培养、组织学和尿素呼气试验阴性，即为感染治愈。意向治疗和符合方案分析的根除率为69.7%（23/33）（95%置信区间= 61-79%）。7例（21.2%）患者出现轻度副作用，如软便和味觉障碍。无一例因不良反应而停药。以左氧氟沙星为基础的三联疗法是标准三联疗法失败后的有效二线治疗。(C)2003年意大利胃肠病学编辑由爱思唯尔有限公司出版。保留所有权利。
Background. Successful eradication of Helicobacter pylori infection after failure of standard triple therapy is difficult. The efficacy and safety of levofloxacin based triple therapy as a first-line therapy has been studied.Aims. The aim was to evaluate the efficacy and tolerability of levofloxacin based therapy after a failed standard triple therapy.Patients. We conducted a prospective, uncontrolled study of a consecutive series of 33 patients who failed eradication with I week of lansoprazole-amoxicillin-clarithromycin triple therapy.Methods. The subjects were retreated with I week of LA-LVFX triple therapy (lansoprazole, 30 mg twice daily; amoxicillin, 1000 mg twice daily; levofloxacin, 200 mg twice daily). Cure of infection was defined as negative results from culture, histology and a urea breath test 4 to 8 weeks after the second-line therapy.Results. The eradication rate was 69.7% (23/33) by both intention-to-treat and per-protocol analyses (95% confidence interval = 61-79%). Seven (21.2%) patients experienced mild side-effects, such as soft stools and taste disturbance. No patient stopped the medication on account of adverse effects.Conclusions. Levofloxacin based triple therapy is an effective second-line treatment after a failed standard triple therapy. (C) 2003 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.